Meeting
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
Authors
Zhi Yang
Chongqing Precision Biotech Co., Ltd., Chongqing, China
Zhi Yang , Shiqi Li , Yu Li , Lin Liu , Zhongtao Yuan , Yingzi Zhang , Le Luo , Lihua Zhang , Yingnian Chen , Qianzhen Zhang , Junjie Shen , Yunyan Li , Linling Wang , Meiling Wang , Wei Zhu , Xiao He , Youcheng Wang , Yancheng Dong , Sanbin Wang , Cheng Qian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04271410
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7026)
DOI
10.1200/JCO.2023.41.16_suppl.7026
Abstract #
7026
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2023 ASCO Annual Meeting
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
First Author: Emily C. Liang
Poster
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
First Author: Frederick L. Locke
Poster
2023 ASCO Annual Meeting
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
First Author: Jian-Qing Mi